Are we ready for immune checkpoint inhibitors for advanced non-small-cell lung cancer?

@article{Mok2016AreWR,
  title={Are we ready for immune checkpoint inhibitors for advanced non-small-cell lung cancer?},
  author={Tony Shu Kam Mok and Herbert H F Loong},
  journal={Lancet},
  year={2016},
  volume={387 10027},
  pages={1488-90}
}
www.thelancet.com Published online December 19, 2015 http://dx.doi.org/10.1016/S0140-6736(15)01308-2 1 Are we ready to embrace the routine use of immune checkpoint inhibitors in patients with advanced stage non-small-cell lung cancer? In The Lancet, Roy Herbst and colleagues report the results of KEYNOTE-010, a randomised phase 2/3 study in 202 academic medical centres in 24 countries that compared two doses of pembrolizumab (2 mg/kg and 10 mg/kg) with docetaxel (75 mg/m2) every 3 weeks in 1034… CONTINUE READING